- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04136392
The Global cVAD Study (cVAD)
May 6, 2021 updated by: Abiomed Inc.
The intent of the Global cVAD Study is to utilize observational data of the ABIOMED, Inc. hemodynamic support devices in real-world settings to drive best practice usage patterns identified through study analysis, to serve as a tool to measure and improve the quality of patient care and to serve as a resource for future research and regulatory filings.
Study Overview
Status
Active, not recruiting
Conditions
Intervention / Treatment
Detailed Description
Ongoing, observational, multicenter, records review of patients receiving the ABIOMED, Inc. hemodynamic support device(s).
To collect in-hospital data, a waiver of consent and authorization will be requested to avoid significant biases in data reporting due to the extremely high mortality.
To collect the post-discharge data on subjects who survive the index hospitalization, an informed consent will be obtained from those subjects or a waiver of informed consent will be used to collect data if the subject was implanted greater than a year from enrollment.
Data will be collected through the review of existing medical records and subject telephone interview.
Clinical follow-up as an office visit is not required for this study protocol.
However, clinical follow-up and event-driven visits (e.g.
re-hospitalizations) may occur as clinically warranted.
At each follow-up time point, a telephone call to the subject will be attempted to obtain updated medical history and self-assessed cardiac function.
In addition to the telephone call, the subject's medical records at the study site will be reviewed for cardiac-related clinic visits and/or cardiac-related re-hospitalization, including echocardiographic imaging.
All data collected for this study will be reported on study specific electronic Case Report Forms (eCRFs) and entered into a controlled 21CFRPart11 compliant Electronic Data Capture (EDC) System by the designee at the participating site.
Monitoring of the study data will be performed according to the study monitoring plan.
Monitoring may be performed on-site or remotely and will not be conducted by anyone involved in data collection.
A Clinical Events Committee (CEC) may be formed by the Sponsor.
If convened, the CEC, an independent adjudication body composed of cardiologists and cardiac surgeons will adjudicate whether the site-reported adverse events and/or MACCE meet the study definitions for these events, and the relatedness of the events to the procedure and the device.
A Steering Committee composed of internationally recognized investigators and experts in the field of interventional cardiology, cardiovascular surgery, cardiac electrophysiology, heart failure and mechanical circulatory support was established to provide technical and scientific oversight of the study.
Study Type
Observational
Enrollment (Anticipated)
20000
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Alabama
-
Birmingham, Alabama, United States, 35233
- University of Alabama at Birmingham
-
-
Arizona
-
Phoenix, Arizona, United States, 85006
- Banner Health Research Institute, Banner Good Samaritan Hospital
-
Tucson, Arizona, United States, 85724
- Banner University Medical Center
-
-
California
-
Los Angeles, California, United States, 90048
- Cedars Sinai
-
Los Angeles, California, United States, 90033
- University of Southern California Keck Hospital
-
Newport Beach, California, United States, 92663
- Hoag Memorial Hospital Presbyterian
-
-
Florida
-
Delray Beach, Florida, United States, 33484
- The Center for Advanced Research Excellence - Delray Medical Center
-
Jacksonville, Florida, United States, 32204
- St. Vincent's Medical Center
-
Miami, Florida, United States, 33136
- University of Miami
-
Miami, Florida, United States, 33133
- Mercy Hospital Research Institute
-
Orlando, Florida, United States, 32806
- Orlando Health
-
-
Georgia
-
Augusta, Georgia, United States, 30901
- University Cardiology Associates
-
Marietta, Georgia, United States, 30060
- Wellstar Research Institute
-
-
Kansas
-
Kansas City, Kansas, United States, 66160
- University of Kansas Hospital
-
-
Kentucky
-
Louisville, Kentucky, United States, 40292
- University of Louisville School of Medicine
-
-
Louisiana
-
New Orleans, Louisiana, United States, 70112
- Tulane University Medical Center
-
New Orleans, Louisiana, United States, 70121
- Ochsner Clinic Health Services Corporation
-
-
Massachusetts
-
Boston, Massachusetts, United States, 02111
- Tufts Medical Center
-
Boston, Massachusetts, United States, 02114
- Massachusetts General Hospital - Corrigan Minehan Heart Center
-
Worcester, Massachusetts, United States, 01608
- St. Vincent Hospital
-
-
Michigan
-
Ann Arbor, Michigan, United States, 48109
- University of Michigan Cardiovascular Center
-
Detroit, Michigan, United States, 48202
- Henry Ford Hospital
-
Detroit, Michigan, United States, 48236
- Ascension St. John Hospital
-
Detroit, Michigan, United States, 48201
- Detroit Medical Center
-
Grand Rapids, Michigan, United States, 49503
- Spectrum Health
-
Royal Oak, Michigan, United States, 48073
- Beaumont Health Center
-
Traverse City, Michigan, United States, 49684
- Munson Medical Center
-
-
Missouri
-
Kansas City, Missouri, United States, 64111
- St. Luke's Hospital
-
-
New Jersey
-
Hackensack, New Jersey, United States, 07601
- Hackensack University Medical Center
-
-
New York
-
Manhasset, New York, United States, 11030
- Northwell Health
-
Mineola, New York, United States, 11501
- Winthrop University Hospital
-
New York, New York, United States, 10032
- Columbia University Medical Center
-
New York, New York, United States, 10029
- Icahn School of Medicine at Mt. Sinai
-
-
Ohio
-
Cincinnati, Ohio, United States, 45255
- Mercy Health Anderson
-
Cleveland, Ohio, United States, 44106
- University Hospital Cleveland Medical Center
-
Dayton, Ohio, United States, 45414
- Good Samaritan Hospital
-
Fairfield, Ohio, United States, 45014
- Mercy Health - Fairfield Hospital Research Center
-
-
Oklahoma
-
Oklahoma City, Oklahoma, United States, 73112
- Integris Cardiovascular Physicians
-
-
Pennsylvania
-
Philadelphia, Pennsylvania, United States, 19141
- Albert Einstein Medical Center
-
Wormleysburg, Pennsylvania, United States, 17043
- Pinnacle Health Cardiovascular Institute Inc.
-
-
Tennessee
-
Jackson, Tennessee, United States, 38301
- Jackson General Hospital
-
Nashville, Tennessee, United States, 37232
- Vanderbilt University Medical Center
-
-
Texas
-
Dallas, Texas, United States, 75204
- Baylor Heart and Vascular Institute
-
Fort Worth, Texas, United States, 76104
- Plaza Medical Center of Fort Worth
-
Houston, Texas, United States, 77030
- The University of Texas - Health Science Center & Medical School at Houston
-
Houston, Texas, United States, 77004
- Baylor College of Medicine - TX Heart Institute
-
-
Virginia
-
Richmond, Virginia, United States, 23219
- Virginia Commonwealth University Health System
-
Roanoke, Virginia, United States, 24014
- Carilion Medical Center
-
-
Washington
-
Seattle, Washington, United States, 98195
- University of Washington
-
-
West Virginia
-
Charleston, West Virginia, United States, 25301
- Charleston Area Medical Center
-
Morgantown, West Virginia, United States, 26506
- West Virginia University Hospital
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
- Child
- Adult
- Older Adult
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Sampling Method
Non-Probability Sample
Study Population
Subjects who received mechanical circulatory support with an ABIOMED, Inc. hemodynamic support device per treating physician's discretion and best practices will be considered eligible for enrollment.
Subjects in whom an attempt was made to implant an ABIOMED, Inc. hemodynamic support device will also be included, even though the attempt was unsuccessful.
An attempt is defined as the ABIOMED, Inc. hemodynamic support catheter came in contact with the subject's skin but was not successfully placed.
Description
Inclusion Criteria:
1. All subjects in the study population are eligible for enrollment at the time of receiving support from an ABIOMED, Inc. hemodynamic support device, or at the time of attempt to implant an ABIOMED, Inc. hemodynamic support device.
Exclusion Criteria:
1. Patients in whom an attempt to implant an ABIOMED, Inc. hemodynamic support device did not occur.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Observational Models: Cohort
- Time Perspectives: Prospective
Cohorts and Interventions
Group / Cohort |
Intervention / Treatment |
---|---|
Eligible Patients
The population to be enrolled in this study includes patients whose intended treatment is to receive mechanical circulatory support with the ABIOMED, Inc. hemodynamic support devices per the treating physician's discretion and best practices.
|
ABIOMED, Inc. hemodynamic support technology are the smallest and least invasive percutaneous ventricular support blood pumps available on the market.
They are routinely used in clinical practice in a variety of clinical scenarios to support patients in prophylactic or emergent settings.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Incidence of Adverse Events including Major Adverse Cardiac and Cerebrovascular Events
Time Frame: January 2025
|
Incidence of Adverse Events including Major Adverse Cardiac and Cerebrovascular Events measured through site-reported events in study EDC through anticipatory primary completion date of January 2025.
|
January 2025
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Investigators
- Study Director: Ali Almedhychy, MD, Abiomed Inc.
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
General Publications
- Fincke R, Hochman JS, Lowe AM, Menon V, Slater JN, Webb JG, LeJemtel TH, Cotter G; SHOCK Investigators. Cardiac power is the strongest hemodynamic correlate of mortality in cardiogenic shock: a report from the SHOCK trial registry. J Am Coll Cardiol. 2004 Jul 21;44(2):340-8. doi: 10.1016/j.jacc.2004.03.060.
- Seyfarth M, Sibbing D, Bauer I, Frohlich G, Bott-Flugel L, Byrne R, Dirschinger J, Kastrati A, Schomig A. A randomized clinical trial to evaluate the safety and efficacy of a percutaneous left ventricular assist device versus intra-aortic balloon pumping for treatment of cardiogenic shock caused by myocardial infarction. J Am Coll Cardiol. 2008 Nov 4;52(19):1584-8. doi: 10.1016/j.jacc.2008.05.065.
- Dixon SR, Henriques JP, Mauri L, Sjauw K, Civitello A, Kar B, Loyalka P, Resnic FS, Teirstein P, Makkar R, Palacios IF, Collins M, Moses J, Benali K, O'Neill WW. A prospective feasibility trial investigating the use of the Impella 2.5 system in patients undergoing high-risk percutaneous coronary intervention (The PROTECT I Trial): initial U.S. experience. JACC Cardiovasc Interv. 2009 Feb;2(2):91-6. doi: 10.1016/j.jcin.2008.11.005.
- O'Neill WW, Kleiman NS, Moses J, Henriques JP, Dixon S, Massaro J, Palacios I, Maini B, Mulukutla S, Dzavik V, Popma J, Douglas PS, Ohman M. A prospective, randomized clinical trial of hemodynamic support with Impella 2.5 versus intra-aortic balloon pump in patients undergoing high-risk percutaneous coronary intervention: the PROTECT II study. Circulation. 2012 Oct 2;126(14):1717-27. doi: 10.1161/CIRCULATIONAHA.112.098194. Epub 2012 Aug 30.
- Griffith BP, Anderson MB, Samuels LE, Pae WE Jr, Naka Y, Frazier OH. The RECOVER I: a multicenter prospective study of Impella 5.0/LD for postcardiotomy circulatory support. J Thorac Cardiovasc Surg. 2013 Feb;145(2):548-54. doi: 10.1016/j.jtcvs.2012.01.067. Epub 2012 Mar 9.
- Anderson MB, Goldstein J, Milano C, Morris LD, Kormos RL, Bhama J, Kapur NK, Bansal A, Garcia J, Baker JN, Silvestry S, Holman WL, Douglas PS, O'Neill W. Benefits of a novel percutaneous ventricular assist device for right heart failure: The prospective RECOVER RIGHT study of the Impella RP device. J Heart Lung Transplant. 2015 Dec;34(12):1549-60. doi: 10.1016/j.healun.2015.08.018. Epub 2015 Sep 8.
- Dangas GD, Kini AS, Sharma SK, Henriques JP, Claessen BE, Dixon SR, Massaro JM, Palacios I, Popma JJ, Ohman M, Stone GW, O'Neill WW. Impact of hemodynamic support with Impella 2.5 versus intra-aortic balloon pump on prognostically important clinical outcomes in patients undergoing high-risk percutaneous coronary intervention (from the PROTECT II randomized trial). Am J Cardiol. 2014 Jan 15;113(2):222-8. doi: 10.1016/j.amjcard.2013.09.008.
- Kovacic JC, Kini A, Banerjee S, Dangas G, Massaro J, Mehran R, Popma J, O'Neill WW, Sharma SK. Patients with 3-vessel coronary artery disease and impaired ventricular function undergoing PCI with Impella 2.5 hemodynamic support have improved 90-day outcomes compared to intra-aortic balloon pump: a sub-study of the PROTECT II trial. J Interv Cardiol. 2015 Feb;28(1):32-40. doi: 10.1111/joic.12166.
- Cohen MG, Ghatak A, Kleiman NS, Naidu SS, Massaro JM, Kirtane AJ, Moses J, Magnus Ohman E, Dzavik V, Palacios IF, Heldman AW, Popma JJ, O'Neill WW. Optimizing rotational atherectomy in high-risk percutaneous coronary interventions: insights from the PROTECT IotaIota study. Catheter Cardiovasc Interv. 2014 Jun 1;83(7):1057-64. doi: 10.1002/ccd.25277. Epub 2013 Nov 18.
- Sjauw KD, Konorza T, Erbel R, Danna PL, Viecca M, Minden HH, Butter C, Engstrom T, Hassager C, Machado FP, Pedrazzini G, Wagner DR, Schamberger R, Kerber S, Mathey DG, Schofer J, Engstrom AE, Henriques JP. Supported high-risk percutaneous coronary intervention with the Impella 2.5 device the Europella registry. J Am Coll Cardiol. 2009 Dec 15;54(25):2430-4. doi: 10.1016/j.jacc.2009.09.018.
- O'Neill WW, Schreiber T, Wohns DH, Rihal C, Naidu SS, Civitello AB, Dixon SR, Massaro JM, Maini B, Ohman EM. The current use of Impella 2.5 in acute myocardial infarction complicated by cardiogenic shock: results from the USpella Registry. J Interv Cardiol. 2014 Feb;27(1):1-11. doi: 10.1111/joic.12080. Epub 2013 Dec 13.
- Cohen MG, Matthews R, Maini B, Dixon S, Vetrovec G, Wohns D, Palacios I, Popma J, Ohman EM, Schreiber T, O'Neill WW. Percutaneous left ventricular assist device for high-risk percutaneous coronary interventions: Real-world versus clinical trial experience. Am Heart J. 2015 Nov;170(5):872-9. doi: 10.1016/j.ahj.2015.08.009. Epub 2015 Aug 15.
- Lemaire A, Anderson MB, Lee LY, Scholz P, Prendergast T, Goodman A, Lozano AM, Spotnitz A, Batsides G. The Impella device for acute mechanical circulatory support in patients in cardiogenic shock. Ann Thorac Surg. 2014 Jan;97(1):133-8. doi: 10.1016/j.athoracsur.2013.07.053. Epub 2013 Oct 1.
- Valgimigli M, Steendijk P, Sianos G, Onderwater E, Serruys PW. Left ventricular unloading and concomitant total cardiac output increase by the use of percutaneous Impella Recover LP 2.5 assist device during high-risk coronary intervention. Catheter Cardiovasc Interv. 2005 Jun;65(2):263-7. doi: 10.1002/ccd.20380.
- Remmelink M, Sjauw KD, Henriques JP, de Winter RJ, Vis MM, Koch KT, Paulus WJ, de Mol BA, Tijssen JG, Piek JJ, Baan J Jr. Effects of mechanical left ventricular unloading by Impella on left ventricular dynamics in high-risk and primary percutaneous coronary intervention patients. Catheter Cardiovasc Interv. 2010 Feb 1;75(2):187-94. doi: 10.1002/ccd.22263.
- Kawashima D, Gojo S, Nishimura T, Itoda Y, Kitahori K, Motomura N, Morota T, Murakami A, Takamoto S, Kyo S, Ono M. Left ventricular mechanical support with Impella provides more ventricular unloading in heart failure than extracorporeal membrane oxygenation. ASAIO J. 2011 May-Jun;57(3):169-76. doi: 10.1097/MAT.0b013e31820e121c.
- Meyns B, Stolinski J, Leunens V, Verbeken E, Flameng W. Left ventricular support by catheter-mounted axial flow pump reduces infarct size. J Am Coll Cardiol. 2003 Apr 2;41(7):1087-95. doi: 10.1016/s0735-1097(03)00084-6.
- Naidu SS. Novel percutaneous cardiac assist devices: the science of and indications for hemodynamic support. Circulation. 2011 Feb 8;123(5):533-43. doi: 10.1161/CIRCULATIONAHA.110.945055. No abstract available.
- Burkhoff D, Naidu SS. The science behind percutaneous hemodynamic support: a review and comparison of support strategies. Catheter Cardiovasc Interv. 2012 Nov 1;80(5):816-29. doi: 10.1002/ccd.24421. Epub 2012 Apr 18.
- Remmelink M, Sjauw KD, Henriques JP, de Winter RJ, Koch KT, van der Schaaf RJ, Vis MM, Tijssen JG, Piek JJ, Baan J Jr. Effects of left ventricular unloading by Impella recover LP2.5 on coronary hemodynamics. Catheter Cardiovasc Interv. 2007 Oct 1;70(4):532-7. doi: 10.1002/ccd.21160.
- Cotter G, Williams SG, Vered Z, Tan LB. Role of cardiac power in heart failure. Curr Opin Cardiol. 2003 May;18(3):215-22. doi: 10.1097/00001573-200305000-00007.
- Torgersen C, Schmittinger CA, Wagner S, Ulmer H, Takala J, Jakob SM, Dunser MW. Hemodynamic variables and mortality in cardiogenic shock: a retrospective cohort study. Crit Care. 2009;13(5):R157. doi: 10.1186/cc8114. Epub 2009 Oct 2.
- Mendoza DD, Cooper HA, Panza JA. Cardiac power output predicts mortality across a broad spectrum of patients with acute cardiac disease. Am Heart J. 2007 Mar;153(3):366-70. doi: 10.1016/j.ahj.2006.11.014.
- Sauren LD, Accord RE, Hamzeh K, de Jong M, van der Nagel T, van der Veen FH, Maessen JG. Combined Impella and intra-aortic balloon pump support to improve both ventricular unloading and coronary blood flow for myocardial recovery: an experimental study. Artif Organs. 2007 Nov;31(11):839-42. doi: 10.1111/j.1525-1594.2007.00477.x.
- Reesink KD, Dekker AL, Van Ommen V, Soemers C, Geskes GG, van der Veen FH, Maessen JG. Miniature intracardiac assist device provides more effective cardiac unloading and circulatory support during severe left heart failure than intraaortic balloon pumping. Chest. 2004 Sep;126(3):896-902. doi: 10.1378/chest.126.3.896.
- Henriques JP, Ouweneel DM, Naidu SS, Palacios IF, Popma J, Ohman EM, O'Neill WW. Evaluating the learning curve in the prospective Randomized Clinical Trial of hemodynamic support with Impella 2.5 versus Intra-Aortic Balloon Pump in patients undergoing high-risk percutaneous coronary intervention: a prespecified subanalysis of the PROTECT II study. Am Heart J. 2014 Apr;167(4):472-479.e5. doi: 10.1016/j.ahj.2013.12.018. Epub 2014 Jan 3.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
July 14, 2017
Primary Completion (Anticipated)
January 1, 2025
Study Completion (Anticipated)
January 1, 2026
Study Registration Dates
First Submitted
October 9, 2019
First Submitted That Met QC Criteria
October 21, 2019
First Posted (Actual)
October 23, 2019
Study Record Updates
Last Update Posted (Actual)
May 10, 2021
Last Update Submitted That Met QC Criteria
May 6, 2021
Last Verified
May 1, 2021
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- cVAD
- USPella (Other Identifier: Abiomed, Inc.)
- The Global cVAD Registry (Other Identifier: Abiomed, Inc.)
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
No
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
Yes
product manufactured in and exported from the U.S.
Yes
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Cardiovascular Diseases
-
Oregon Health and Science UniversityCompletedCardiovascular Disease | Cardiovascular Risk FactorsUnited States
-
Medical College of WisconsinRecruitingCardiovascular Diseases | Cardiovascular Risk Factor | Cardiovascular HealthUnited States
-
Hospital Mutua de TerrassaCompleted
-
Groupe Hospitalier Paris Saint JosephTerminatedCARDIOVASCULAR DISEASESFrance
-
Women's College HospitalUniversity Health Network, Toronto; Sunnybrook Health Sciences Centre; Brigham... and other collaboratorsUnknownCARDIOVASCULAR DISEASESCanada, United States
-
University of FloridaUniversity of Alabama at Birmingham; Brown UniversityCompletedCardiovascular Disease | Psychosocial Influence on Cardiovascular DiseaseUnited States
-
Nanjing Medical UniversityRecruiting
-
Centre Hospitalier Universitaire de la RéunionRecruitingCardiovascular DiseaseFrance
-
National Heart, Lung, and Blood Institute (NHLBI)RecruitingCardiovascular DiseaseUnited States
-
National Heart, Lung, and Blood Institute (NHLBI)RecruitingCardiovascular DiseaseUnited States
Clinical Trials on ABIOMED, Inc. hemodynamic support devices
-
Oregon Health and Science UniversityTerminatedCritically IllUnited States
-
Medical College of WisconsinTerminatedLeber's Hereditary Optic Neuropathy (LHON)United States
-
Zekai Tahir Burak Women's Health Research and Education...UnknownRespiratory Distress Syndrome | PrematurityTurkey
-
Odense University HospitalCharite University, Berlin, Germany; Hannover Medical School; Aarhus University... and other collaboratorsActive, not recruitingAcute Myocardial Infarction | Cardiogenic Shock AcuteGermany, Denmark, United Kingdom
-
VitazUniversity GhentRecruitingPressure Ulcer | Pressure Injury | Decubitus UlcerBelgium
-
University Hospital, LilleUnknownHeart Failure | Aortic StenosisFrance
-
Soovu Labs Inc.University of Washington; Northern California Research CorporationCompletedLow Back Pain | Chronic Pain | Analgesia | HeatUnited States
-
University of ZurichCompleted
-
McGill UniversityCompletedChronic Obstructive Pulmonary Disease | DyspneaCanada
-
Erasmus Medical CenterInterscope, Inc.RecruitingAcute Pancreatitis | Necrosis; Pancreas, Acute (Infectious)Netherlands, United States, Italy, Germany, Denmark, United Kingdom